Diabetic FootPhase 4NCT03209466
Chlorhexidine Gluconate Solution at 0.125% vs Placebo for the Healing of Grade IIB Ulcers of Diabetic Foot
A Phase 4 study testing Chlorhexidine gluconate at 0.125% in people with Diabetic Foot, run by Universidad de Guanajuato at 1 site in Mexico.
Trial summary
There is controversy regarding the utility of antiseptics in wound management for diabetic foot ulcer syndrome. The aim of this study is to assess chlorhexidine gluconate at 0.125% vs. saline solution to reduce the ulcerated area in patients with diabetic ulcer syndrome. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Diabetic Foot
- What is being tested?
- Chlorhexidine gluconate at 0.125%
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 35 participants
- Where
- 1 siteMexico
- Study dates
- 11 May 2017to 30 Dec 2020
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Ambulatory patients of both sex over age of 18 years old with diabetes mellitus that present an ulcer caused by diabetic foot syndrome with an extension from skin to tendon or join capsule and infected, classified as Texas IIB.
Who cannot join
- Patients lost to follow up and those that voluntary leave the study.
Trial locations and contacts
1 site in 1 country.
Mexico1 site, 1 recruiting
- Recruiting
Universidad de Guanajuato
León, Guanajuato, 37320
Juan M Muñoz, MD, jmunozb@me.com
About this study
Official title: Standard Management and Chlorhexidine Gluconate Solution at 0.125% Versus Standard Management and Physiological Saline Sterile Solution for Healing Grade IIB Ulcers in Diabetic Foot Syndrome: Clinical Trial
There is controversy regarding the utility of antiseptics in wound management for diabetic foot ulcer syndrome. The aim of this study is to assess chlorhexidine gluconate at 0.125% vs. saline solution to reduce the ulcerated area in patients with diabetic ulcer syndrome. A clinical trial model to evaluate modifications in size and area is proposed. Patients to be included will be those with diabetic foot ulcers Graded II accordingly to the University of Texas wound classification system.
Read the detailed description
This study will be done in Hospital General de Leon
Population: People with diabetic foot syndrome grade IIb in Guanajuato Mexico
Universe: People with diabetes mellitus and diabetic foot syndrome in Guanajuato
Sample: Patients with diabetes mellitus over age of 18 years old, that present to the wound´s clinic of Hospital General Leon with diabetic foot ulcers classified as Texas IIB. This clinic provides services to patients in Guanajuato with diabetic foot syndrome, including them in a multidisciplinary management program.
Sample size calculation: A minimal sample of 35 patients for each arm of the study was calculated. Each study arm will be balanced considering the size. Potency was calculated at 0.8 and alpha value at 0-5, to detect a difference of 25% on the ulcer size.
Methodology:
Will be invited to participate in the study consecutive patients with diabetes mellitus presented with diabetic foot ulcers Graded II accordingly to the University of Texas wound classification system, in the area of Clinical wounds of Hospital General Leon between May and December 2017.
After explaining the study information and check it is understandable, the investigators provide the sheet to signed the informed consent.
Subsequently selected patients will be measure the ankle brachial index and determine the absence of vascular compromise.
Medical history with emphasis on analyzing clinical data, including the characteristics of the ulcer (type of exudate, measured surface area affected , type of tissue involved in the ulcer to its depth ) and biochemical parameters will be made.
Patients will be weighed and measured at the first visit and those who don't have biochemical data will be requested to collect this information in subsequent follow-up visits.
The participants will be then treated with the principles of the standard treatment, under the following criteria:
- Remove the ulcer exudate by spraying one of the two ingredients making mechanical drive for 5 minutes, or until completely negative to the visual evidence of exudate.
- Completely remove hyperkeratosis and devitalized tissue from the periphery of the ulcer with cutting material dissection with sterile dressing and drag, until visually eliminate the exudate.
- The treated area is dried.
- Two photographs at a distance of 20 cm perpendicular to the ulcer will be taken, covering a 1 square centimeter reference for measuring the area affected by diabetic foot ulcer syndrome.
- The solution will be applied in a blinded way to the ulcer and covered with sterile gauze for 24 hours.
- The patient will be instructed to continue treatment every 24 hours as follows:
- Sterile gauze will be removed and continuously irrigate for 5 seconds with the ingredient that was assigned.
- Undiscovered for 24 hours, until the next day irrigation gauze area will be placed. Also need to avoid contact with any surface over the affected area until the next assessment.
- Perform the same strategy for 24 hours, and on day 7 must go to the wound clinic to clinical evaluation.
- Every 7 days until complete 6 views, clinical evaluation is performed, irrigation with the selected ingredient and it will take 2 pictures at a distance of 20 cm perpendicular to the ulcer again, covering a reference of 1 square centimeter to measure the area affected by the diabetic foot ulcer syndrome.
Every week during the following 6 weeks, in the wound clinic consultation, it will be measured and gather information of the following elements:
- Ulcer area in square millimeters.
- Color of the ulcer.
- Type of exudate; turbid, serous.
- Type of tissue involved in the ulcer to its depth. If any patients have increased intensity of the signs and symptoms of diabetic foot syndrome, classified as a major step on the scale of ulcers Classification System of the University of Texas, perform analysis and comprehensive treatment will be redefined according to the suggestions of ulcer classification system of the University of Texas.
Cleaning material for the ulcer:
Ingredient 1: Preparation of spray application of chlorhexidine gluconate 0.125%.
Ingredient 2: Preparation of spray application of physiological saline sterile solution.
Method of application of ingredients as described previously. Method of randomization: will be effected since the fabrication of the ingredient by assigning a code number to each of the bottles that contained. Those bottles will have identical presentations, and will balance for the sample size. The code will not be known by the patient, observer and analyst. Only be known by one of the advisors.
Statistical methods:
The description of the data, in the case of non-numerical variables will be performed by reporting proportions and confidence interval of 95 % (95 %) in the case of numerical variables, the description will be made based on averages and standard deviation or medians and Q1- Q3 range, depending on the result of the Kolmogorov-Smirnov test to evaluate the Gaussian distribution of the data.
Comparison of numerical variables were not performed by Chi square test. Comparison of the rates of reduction in the size of ulcers of diabetic foot syndrome for both treatments will be based on the t test for independent samples or by Kruskal- Wallis test, depending on data distribution.
In all cases be considered as the significance level alpha value <0.05.
- Conditions
- Diabetic Foot
- Being tested
- Chlorhexidine gluconate at 0.125%, Placebo Comparator with physiological saline sterile solution
- Keywords
- Chlorhexidine gluconate, Diabetic foot ulcer syndrome, Wound healing
- Medical subject headings
- Diabetic Foot
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Chlorhexidine gluconate at 0.125%Drug
Application every 24 hours, six weeks Intervention: Procedure: chlorhexidine gluconate
Placebo Comparator with physiological saline sterile solutionDrug
Standard management and physiological saline sterile solution with application every 24 hours, six weeks Intervention.
| Study group | Role | What they receive |
|---|---|---|
| Standard management and Chlorhexidine gluconate at 0.125% | Experimental | Application every 24 hours, six weeks Intervention: Procedure: chlorhexidine gluconate Receives: Drug: Chlorhexidine gluconate at 0.125% |
| Standard management and physiological saline sterile solution | Placebo comparator | Application every 24 hours, six weeks Intervention: Other: physiological saline sterile solution Receives: Drug: Placebo Comparator with physiological saline sterile solution |
What is being measured
The primary outcome is the main question the study is designed to answer.
Ulcerated area
area of diabetic foot ulcer measured with photographic register using a visual control of dimensions and a dedicated software for measurements.
Measured: Up to 6 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jul 2017
- Study start11 May 2017
- Primary completion15 Dec 2020 (estimated)
- Study completion30 Dec 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Diabetic FootStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 35 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Universidad de Guanajuato
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jose Antonio de Jesus Alvarez Canales, Universidad de Guanajuato
- Investigators
- Alejandro E Macias, MD, Study director, Universidad de Guanajuato
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03209466
- Sponsor's protocol ID
- CHXDF
- Status last verified
- Mar 2019
- First submitted
- 1 Jul 2017
- Last updated
- 15 Mar 2019
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: None IPD will be share; only group data analyzed
Publications
Frykberg RG, Zgonis T, Armstrong DG, Driver VR, Giurini JM, Kravitz SR, Landsman AS, Lavery LA, Moore JC, Schuberth JM, Wukich DK, Andersen C, Vanore JV; American College of Foot and Ankle Surgeons. Diabetic foot disorders. A clinical practice guideline (2006 revision). J Foot Ankle Surg. 2006 Sep-Oct;45(5 Suppl):S1-66. doi: 10.1016/S1067-2516(07)60001-5.
PubMed 17280936Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet. 2005 Nov 12;366(9498):1719-24. doi: 10.1016/S0140-6736(05)67698-2.
PubMed 16291066Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet. 2001 Jul 14;358(9276):135-8. doi: 10.1016/s0140-6736(01)05321-1.
PubMed 11463434
Study at a glance
From the registry record, last updated by the sponsor on 15 Mar 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Standard Management and Chlorhexidine Gluconate Solution at 0.125% Versus Standard Management and Physiological Saline Sterile Solution for Healing Grade IIB Ulcers in Diabetic Foot Syndrome: Clinical Trial
- ClinicalTrials.gov ID
- NCT03209466
- Acronym / sponsor ID
- CHXDF
- Conditions
- Diabetic Foot
- Keywords
- Chlorhexidine gluconate, Diabetic foot ulcer syndrome, Wound healing
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 35 participants (estimated)
- Lead sponsor
- Universidad de GuanajuatoUniversity, hospital or other
- Study start
- 11 May 2017 (actual)
- Primary completion
- 15 Dec 2020 (estimated)
- Study completion
- 30 Dec 2020 (estimated)
- First posted
- 6 Jul 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
There is controversy regarding the utility of antiseptics in wound management for diabetic foot ulcer syndrome. The aim of this study is to assess chlorhexidine gluconate at 0.125% vs. saline solution to reduce the ulcerated area in patients with diabetic ulcer syndrome. A clinical trial model to evaluate modifications in size and area is proposed. Patients to be included will be those with diabetic foot ulcers Graded II accordingly to the University of Texas wound classification system.
Detailed description
This study will be done in Hospital General de Leon
Population: People with diabetic foot syndrome grade IIb in Guanajuato Mexico
Universe: People with diabetes mellitus and diabetic foot syndrome in Guanajuato
Sample: Patients with diabetes mellitus over age of 18 years old, that present to the wound´s clinic of Hospital General Leon with diabetic foot ulcers classified as Texas IIB. This clinic provides services to patients in Guanajuato with diabetic foot syndrome, including them in a multidisciplinary management program.
Sample size calculation: A minimal sample of 35 patients for each arm of the study was calculated. Each study arm will be balanced considering the size. Potency was calculated at 0.8 and alpha value at 0-5, to detect a difference of 25% on the ulcer size.
Methodology:
Will be invited to participate in the study consecutive patients with diabetes mellitus presented with diabetic foot ulcers Graded II accordingly to the University of Texas wound classification system, in the area of Clinical wounds of Hospital General Leon between May and December 2017.
After explaining the study information and check it is understandable, the investigators provide the sheet to signed the informed consent.
Subsequently selected patients will be measure the ankle brachial index and determine the absence of vascular compromise.
Medical history with emphasis on analyzing clinical data, including the characteristics of the ulcer (type of exudate, measured surface area affected , type of tissue involved in the ulcer to its depth ) and biochemical parameters will be made.
Patients will be weighed and measured at the first visit and those who don't have biochemical data will be requested to collect this information in subsequent follow-up visits.
The participants will be then treated with the principles of the standard treatment, under the following criteria:
- Remove the ulcer exudate by spraying one of the two ingredients making mechanical drive for 5 minutes, or until completely negative to the visual evidence of exudate.
- Completely remove hyperkeratosis and devitalized tissue from the periphery of the ulcer with cutting material dissection with sterile dressing and drag, until visually eliminate the exudate.
- The treated area is dried.
- Two photographs at a distance of 20 cm perpendicular to the ulcer will be taken, covering a 1 square centimeter reference for measuring the area affected by diabetic foot ulcer syndrome.
- The solution will be applied in a blinded way to the ulcer and covered with sterile gauze for 24 hours.
- The patient will be instructed to continue treatment every 24 hours as follows:
- Sterile gauze will be removed and continuously irrigate for 5 seconds with the ingredient that was assigned.
- Undiscovered for 24 hours, until the next day irrigation gauze area will be placed. Also need to avoid contact with any surface over the affected area until the next assessment.
- Perform the same strategy for 24 hours, and on day 7 must go to the wound clinic to clinical evaluation.
- Every 7 days until complete 6 views, clinical evaluation is performed, irrigation with the selected ingredient and it will take 2 pictures at a distance of 20 cm perpendicular to the ulcer again, covering a reference of 1 square centimeter to measure the area affected by the diabetic foot ulcer syndrome.
Every week during the following 6 weeks, in the wound clinic consultation, it will be measured and gather information of the following elements:
- Ulcer area in square millimeters.
- Color of the ulcer.
- Type of exudate; turbid, serous.
- Type of tissue involved in the ulcer to its depth. If any patients have increased intensity of the signs and symptoms of diabetic foot syndrome, classified as a major step on the scale of ulcers Classification System of the University of Texas, perform analysis and comprehensive treatment will be redefined according to the suggestions of ulcer classification system of the University of Texas.
Cleaning material for the ulcer:
Ingredient 1: Preparation of spray application of chlorhexidine gluconate 0.125%.
Ingredient 2: Preparation of spray application of physiological saline sterile solution.
Method of application of ingredients as described previously. Method of randomization: will be effected since the fabrication of the ingredient by assigning a code number to each of the bottles that contained. Those bottles will have identical presentations, and will balance for the sample size. The code will not be known by the patient, observer and analyst. Only be known by one of the advisors.
Statistical methods:
The description of the data, in the case of non-numerical variables will be performed by reporting proportions and confidence interval of 95 % (95 %) in the case of numerical variables, the description will be made based on averages and standard deviation or medians and Q1- Q3 range, depending on the result of the Kolmogorov-Smirnov test to evaluate the Gaussian distribution of the data.
Comparison of numerical variables were not performed by Chi square test. Comparison of the rates of reduction in the size of ulcers of diabetic foot syndrome for both treatments will be based on the t test for independent samples or by Kruskal- Wallis test, depending on data distribution.
In all cases be considered as the significance level alpha value <0.05.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Standard management and Chlorhexidine gluconate at 0.125% | Experimental | Drug: Chlorhexidine gluconate at 0.125%Application every 24 hours, six weeks Intervention: Procedure: chlorhexidine gluconate |
| Standard management and physiological saline sterile solution | Placebo comparator | Drug: Placebo Comparator with physiological saline sterile solutionApplication every 24 hours, six weeks Intervention: Other: physiological saline sterile solution |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Ambulatory patients of both sex over age of 18 years old with diabetes mellitus that present an ulcer caused by diabetic foot syndrome with an extension from skin to tendon or join capsule and infected, classified as Texas IIB.
Key exclusion criteria (1 listed)
- Patients lost to follow up and those that voluntary leave the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Chlorhexidine gluconate at 0.125%Application every 24 hours, six weeks Intervention: Procedure: chlorhexidine gluconate | Drug | Standard management and Chlorhexidine gluconate at 0.125% |
| Placebo Comparator with physiological saline sterile solutionStandard management and physiological saline sterile solution with application every 24 hours, six weeks Intervention. | Drug | Standard management and physiological saline sterile solution |
Primary outcome
Ulcerated area
Time frame: Up to 6 weeks
area of diabetic foot ulcer measured with photographic register using a visual control of dimensions and a dedicated software for measurements.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Mar 2019.
- Background: PubMed 17280936Frykberg RG, Zgonis T, Armstrong DG, Driver VR, Giurini JM, Kravitz SR, Landsman AS, Lavery LA, Moore JC, Schuberth JM, Wukich DK, Andersen C, Vanore JV; American College of Foot and Ankle Surgeons. Diabetic foot disorders. A clinical practice guideline (2006 revision). J Foot Ankle Surg. 2006 Sep-Oct;45(5 Suppl):S1-66. doi: 10.1016/S1067-2516(07)60001-5.
- Results publication: PubMed 16291066Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet. 2005 Nov 12;366(9498):1719-24. doi: 10.1016/S0140-6736(05)67698-2.
- Results publication: PubMed 11463434Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet. 2001 Jul 14;358(9276):135-8. doi: 10.1016/s0140-6736(01)05321-1.
- Individual participant dataSharing planned: No. None IPD will be share; only group data analyzed
Related trials for Diabetic Foot
Not yet recruiting
Better Care Closer to Home: Enhancing Primary and Community Care
Diabetic Foot Disease, Recurrence
Not yet recruiting
Comparison of Negative Pressure Wound Therapy Versus Moist Wound Dressing in Diabetic Foot Ulcer Patients
Diabetic Foot Ulcer
RecruitingPhase 2
Evaluation of the Safety and Efficacy of Live ASCs in the Treatment of Diabetic Foot Syndrome.
Diabetic Foot Ulcer
RecruitingObservational study
Efficacy and Safety of a Nitric Oxide Generating Dressing for Diabetic Foot Ulcers (ONWARD)
Diabetic Foot Ulcers (DFUs)
RecruitingObservational study
Factors Associated With an Evolution in the Quality of Life of Diabetic Patients With Chronic, Wound-free Charcot Foot
Charcot Joint of Foot, Osteoarthropathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alejandro E Macias, MD study director
Universidad de Guanajuato
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Chlorhexidine gluconate at 0.125% in people with Diabetic Foot, run by Universidad de Guanajuato at 1 site in Mexico.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 15 Mar 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Mexico. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Jose A Alvarez, PhD (52 477 2674900 ext. 4643, alvarez_ja@me.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Ulcerated area (time frame: Up to 6 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03209466, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Mar 2019; AzTrials last refreshed its copy on 31 Oct 2026.